Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016', provides in depth analysis on Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted pipeline therapeutics. The report provides comprehensive information on the Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - The report reviews Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects - The report assesses Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) Overview 7 Therapeutics Development 8 Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Products under Development by Stage of Development 8 Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Products under Development by Therapy Area 9 Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Products under Development by Indication 10 Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Products under Development by Companies 14 Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Therapeutics Assessment 17 Assessment by Monotherapy/Combination Products 17 Assessment by Mechanism of Action 18 Assessment by Route of Administration 19 Assessment by Molecule Type 21 Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Companies Involved in Therapeutics Development 23 Arrien Pharmaceuticals, LLC 23 Confluence Life Sciences, Inc. 24 Corvus Pharmaceuticals, Inc. 25 Genentech, Inc. 26 Japan Tobacco Inc. 27 Novartis AG 28 Principia Biopharma Inc. 29 Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Drug Profiles 30 ARN-4079 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 JTE-051 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 pazopanib hydrochloride - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 pazopanib hydrochloride + pembrolizumab - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 PRN-694 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Small Molecule to Inhibit ITK and TXK for Immunology and Oncology - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Small Molecule to Inhibit ITK for Asthma - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Small Molecule to Inhibit ITK for Autoimmune Disorders, Chronic Inflammation and Oncology - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Small Molecules to Inhibit ITK for Oncology - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Dormant Projects 45 Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Featured News & Press Releases 46 Jul 21, 2016: Mateon Announces Enrollment of First Patient in Phase 2 Portion of PAZOFOS Study in Recurrent Ovarian Cancer 46 Mar 16, 2015: Cancer drug may reduce bleeding in patients with rare genetic disorder, HHT 46 Apr 01, 2014: Results from phase III patient preference study of GSK's Votrient (pazopanib) vs. Sutent (sunitinib) in advanced renal cell carcinoma published in Journal of Clinical Oncology 47 Mar 31, 2014: Votrient as maintenance therapy for advanced ovarian cancer in the EU 48 Aug 21, 2013: Pazopanib shows better quality-of-life in advanced kidney cancer 49 Aug 07, 2013: GSK seeks additional indication approval for Votrient from EMA 50 Jul 11, 2013: GlaxoSmithKline's cancer drug Votrient receives full EU approval 50 Jun 01, 2013: GSK's Votrient Meets Primary Endpoint In Phase III Clinical Trial As Maintenance Therapy In Women With Advanced Epithelial Ovarian Cancer 51 Jan 08, 2013: Combination Of Pazopanib And Paclitaxel May Slow Anaplastic Thyroid Cancer, Mayo Clinic Study Shows 52 Oct 01, 2012: GlaxoSmithKline's Votrient Meets Primary Endpoint In Pivotal Phase III Study Of Advanced Renal Cell Carcinoma 53 Aug 07, 2012: GlaxoSmithKline Receives Marketing Authorization From European Commission For Pazopanib 54 May 25, 2012: GSK Receives Positive Opinion From European CHMP For Pazopanib In Treatment Of Patients With Certain Advanced Soft Tissue Sarcomas 55 Apr 26, 2012: GSK's Votrient Receives FDA Approval For Treatment Of Advanced Soft Tissue Sarcoma 55 Mar 20, 2012: GSK Announces Positive Vote From FDA Panel For Pazopanib In Certain Advanced Soft Tissue Sarcomas 55 Mar 02, 2012: PHARMAC To Fund GSK's Kidney Cancer Drug, Votrient 56 Appendix 57 Methodology 57 Coverage 57 Secondary Research 57 Primary Research 57 Expert Panel Validation 57 Contact Us 57 Disclaimer 58
List of Tables
Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Early Stage Products, H2 2016 13 Number of Products under Development by Companies, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Development by Companies, H2 2016 (Contd..1) 16 Assessment by Monotherapy/Combination Products, H2 2016 17 Number of Products by Stage and Mechanism of Action, H2 2016 18 Number of Products by Stage and Route of Administration, H2 2016 20 Number of Products by Stage and Molecule Type, H2 2016 22 Pipeline by Arrien Pharmaceuticals, LLC, H2 2016 23 Pipeline by Confluence Life Sciences, Inc., H2 2016 24 Pipeline by Corvus Pharmaceuticals, Inc., H2 2016 25 Pipeline by Genentech, Inc., H2 2016 26 Pipeline by Japan Tobacco Inc., H2 2016 27 Pipeline by Novartis AG, H2 2016 28 Pipeline by Principia Biopharma Inc., H2 2016 29 Dormant Projects, H2 2016 45
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
